MEREO BIOPHARMA GROUP PL-ADR (MREO) Fundamental Analysis & Valuation

NASDAQ:MREO • US5894921072

Current stock price

0.26 USD
-0.01 (-3.13%)
At close:
0.2641 USD
+0 (+1.58%)
After Hours:

This MREO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MREO Profitability Analysis

1.1 Basic Checks

  • In the past year MREO has reported negative net income.
  • MREO had negative earnings in 4 of the past 5 years.
  • MREO had a negative operating cash flow in each of the past 5 years.
MREO Yearly Net Income VS EBIT VS OCF VS FCFMREO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • MREO has a worse Return On Assets (-91.45%) than 73.40% of its industry peers.
  • The Return On Equity of MREO (-102.63%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -91.45%
ROE -102.63%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MREO Yearly ROA, ROE, ROICMREO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600 800 1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 73.40%, MREO belongs to the top of the industry, outperforming 80.97% of the companies in the same industry.
  • MREO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MREO Yearly Profit, Operating, Gross MarginsMREO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MREO Health Analysis

2.1 Basic Checks

  • MREO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MREO Yearly Shares OutstandingMREO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
MREO Yearly Total Debt VS Total AssetsMREO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • MREO has an Altman-Z score of -11.93. This is a bad value and indicates that MREO is not financially healthy and even has some risk of bankruptcy.
  • MREO has a Altman-Z score of -11.93. This is in the lower half of the industry: MREO underperforms 76.31% of its industry peers.
  • MREO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.93
ROIC/WACCN/A
WACCN/A
MREO Yearly LT Debt VS Equity VS FCFMREO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 10.46 indicates that MREO has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 10.46, MREO belongs to the best of the industry, outperforming 81.17% of the companies in the same industry.
  • MREO has a Quick Ratio of 10.46. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.46, MREO belongs to the best of the industry, outperforming 81.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.46
Quick Ratio 10.46
MREO Yearly Current Assets VS Current LiabilitesMREO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MREO Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.17% over the past year.
EPS 1Y (TTM)6.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MREO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
  • Based on estimates for the next years, MREO will show a very strong growth in Revenue. The Revenue will grow by 188.00% on average per year.
EPS Next Y86.09%
EPS Next 2Y41.09%
EPS Next 3Y35.9%
EPS Next 5Y14.87%
Revenue Next Year4881.33%
Revenue Next 2Y780.15%
Revenue Next 3Y325.88%
Revenue Next 5Y188%

3.3 Evolution

MREO Yearly Revenue VS EstimatesMREO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MREO Yearly EPS VS EstimatesMREO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2031 2032 2033 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. MREO Valuation Analysis

4.1 Price/Earnings Ratio

  • MREO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MREO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MREO Price Earnings VS Forward Price EarningsMREO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MREO Per share dataMREO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MREO's earnings are expected to grow with 35.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.09%
EPS Next 3Y35.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MREO Dividend Analysis

5.1 Amount

  • MREO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MREO Fundamentals: All Metrics, Ratios and Statistics

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (5/1/2026, 5:39:02 PM)

After market: 0.2641 +0 (+1.58%)

0.26

-0.01 (-3.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-19
Earnings (Next)05-11
Inst Owners43.42%
Inst Owner Change0.07%
Ins Owners0.86%
Ins Owner Change0%
Market Cap41.50M
Revenue(TTM)500.00K
Net Income(TTM)-41.99M
Analysts81.43
Price Target1.79 (588.46%)
Short Float %26.12%
Short Ratio4.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.7%
Min EPS beat(2)23.76%
Max EPS beat(2)59.64%
EPS beat(4)2
Avg EPS beat(4)-415.73%
Min EPS beat(4)-1246.69%
Max EPS beat(4)59.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-400%
EPS NY rev (1m)9.99%
EPS NY rev (3m)9.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)-22.93%
Revenue NY rev (3m)-22.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 83
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.26
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -91.45%
ROE -102.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.4%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.46
Quick Ratio 10.46
Altman-Z -11.93
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y86.09%
EPS Next 2Y41.09%
EPS Next 3Y35.9%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year4881.33%
Revenue Next 2Y780.15%
Revenue Next 3Y325.88%
Revenue Next 5Y188%
EBIT growth 1Y15.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.27%
EBIT Next 3Y41.45%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

MEREO BIOPHARMA GROUP PL-ADR / MREO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MREO.


Can you provide the valuation status for MEREO BIOPHARMA GROUP PL-ADR?

ChartMill assigns a valuation rating of 1 / 10 to MEREO BIOPHARMA GROUP PL-ADR (MREO). This can be considered as Overvalued.


What is the profitability of MREO stock?

MEREO BIOPHARMA GROUP PL-ADR (MREO) has a profitability rating of 1 / 10.


Can you provide the financial health for MREO stock?

The financial health rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) is 7 / 10.


What is the expected EPS growth for MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

The Earnings per Share (EPS) of MEREO BIOPHARMA GROUP PL-ADR (MREO) is expected to grow by 86.09% in the next year.